 | |
Subscribe to our Email List
| |
Verona Pharma's longer term focus is to investigate and apply new synthetic and analytical chemical techniques to the discovery and development of novel polysaccharide drugs useful in the treatment of a wide range of respiratory and, potentially, inflammatory diseases. The polysaccharide, heparin, is a well known anti-coagulant that has been shown to have anti-inflammatory effects in a range of diseases, but the use of which is limited by its anti-coagulant effect. Verona Pharma has identified in certain marine organisms, such as starfish, a natural source of novel anti-inflammatory polysaccharide (NAIPS) without anti-coagulant actions. The Company is working in collaboration with Glycomar Limited of Scotland and Glycores 2000 S.r.l. of Italy to source and screen various naturally occurring and synthesised novel polysaccharide compounds as potential lead candidates for its NAIPs programme.
| | |
